JPI-547, a Dual Inhibitor of PARP/Tankyrase, Shows Antitumor Activity Against Pancreatic Cancers with Homologous Recombination Repair Deficiency or Wnt-Addiction
Kyoung-Seok Oh(Seoul National University Hospital), Do‐Youn Oh(Seoul National University)
Cited by 3
Related Papers
WEE1 inhibition reverses trastuzumab resistance in HER2-positive cancers
|Gastric Cancer|2021|32
Immunomodulatory effects of trastuzumab deruxtecan through the cGAS-STING pathway in gastric cancer cells
|Cell Communication and Signaling|2024|18
Inhibition of WEE1 Potentiates Sensitivity to PARP Inhibitor in Biliary Tract Cancer
|Cancer Research and Treatment|2021|13
Therapeutic potential of BOLD-100, a GRP78 inhibitor, enhanced by ATR inhibition in pancreatic ductal adenocarcinoma
|Cell Communication and Signaling|2025|4
YAP as a therapeutic target to reverse trastuzumab resistance
|Gastric Cancer|2025|0